Leerink Partnrs Expects Weaker Earnings for Replimune Group

Replimune Group, Inc. (NASDAQ:REPL) – Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($2.93) for the year, down from their prior forecast of ($2.82). The consensus estimate for Replimune Group’s current full-year earnings is ($2.88) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.69) EPS and FY2026 earnings at ($2.22) EPS.

Several other equities analysts have also issued reports on REPL. Jefferies Financial Group boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $19.29.

Replimune Group Trading Down 0.5 %

NASDAQ:REPL opened at $14.03 on Monday. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm’s fifty day moving average is $12.57 and its 200-day moving average is $11.77. The firm has a market cap of $959.93 million, a P/E ratio of -4.60 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09).

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in REPL. Braidwell LP raised its stake in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Replimune Group during the fourth quarter worth $21,754,000. Tang Capital Management LLC grew its holdings in Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock worth $32,697,000 after buying an additional 1,500,000 shares in the last quarter. State Street Corp raised its position in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after acquiring an additional 1,083,633 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Buying and Selling

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.80% of the stock is owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.